<DOC>
	<DOCNO>NCT00481559</DOCNO>
	<brief_summary>This protocol treatment toxic plasma methotrexate concentration ( &gt; 1 micromole per liter ) patient delay methotrexate clearance due impair renal function</brief_summary>
	<brief_title>Treatment Protocol Voraxaze Patients Experiencing Risk Methotrexate Toxicity</brief_title>
	<detailed_description>This treatment protocol available cost recovery basis IRB-approved Investigators treat eligible patient site US . In order continue make Voraxaze™ available follow FDA approval prior commercially available . Protherics needs charge product , cost obtain Voraxaze™ Open-Label Treatment Protocol . Protherics permit FDA regulation ( 21 CFR 312.8 ) charge Voraxaze , recover cost associate manufacture , research development , handling , include commercial cost ( profit ) . Patient eligibility base MTX concentration laboratory value obtain per standard care . Once Investigator identify potential patient , he/she contact Voraxaze central call center ( 1-877-398-9829 ) receive information regard drug shipment . Eligible patient routine demographic , MTX , Voraxaze therapy information collect . Each patient receive single dose Voraxaze 50 Units/kg bolus intravenous injection 5 minute . In addition Voraxaze , patient continue receive standard care treatment include leucovorin therapy , supportive care hydration , alkalinization urine , necessary , hemoperfusion/dialysis .</detailed_description>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Male female patient age experience delay MTX clearance due impair renal function eligible receive Voraxaze toxic plasma MTX concentration ( &gt; 1 micromole per liter ) . Voraxaze indicate use patient exhibit expect clearance MTX ( plasma MTX concentration within 2 standard deviation mean MTX excretion curve specific dose MTX administer ) normal mildly impaired renal function potential risk sub therapeutic exposure MTX . Patients know hypersensitivity Voraxaze ( glucarpidase , carboxypeptidases ) Patients intolerant lactose food ( e.g. , dairy product ) still receive Voraxaze .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Voraxaze</keyword>
	<keyword>glucarpidase</keyword>
	<keyword>carboxypeptidase</keyword>
	<keyword>cancer</keyword>
	<keyword>lymphoma</keyword>
	<keyword>leukemia</keyword>
	<keyword>osteosarcoma</keyword>
	<keyword>methotrexate</keyword>
	<keyword>delay elimination</keyword>
	<keyword>renal insufficiency</keyword>
	<keyword>toxicity</keyword>
</DOC>